What is the official website of SGS Pharma ?

The official website of SGS Pharma is https://www.sgs.com/en/industry/pharma.

What is SGS Pharma's cybersecurity risk score?

SGS Pharma has an AI-generated cybersecurity risk score of 759 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has SGS Pharma experienced?

According to Rankiteo, SGS Pharma currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has SGS Pharma been affected by any supply chain cyber incidents ?

According to Rankiteo, SGS Pharma has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does SGS Pharma have SOC 2 Type 1 certification ?

According to Rankiteo, SGS Pharma is not certified under SOC 2 Type 1.

Does SGS Pharma have SOC 2 Type 2 certification ?

According to Rankiteo, SGS Pharma does not hold a SOC 2 Type 2 certification.

Does SGS Pharma comply with GDPR ?

According to Rankiteo, SGS Pharma is not listed as GDPR compliant.

Does SGS Pharma have PCI DSS certification ?

According to Rankiteo, SGS Pharma does not currently maintain PCI DSS compliance.

Does SGS Pharma comply with HIPAA ?

According to Rankiteo, SGS Pharma is not compliant with HIPAA regulations.

Does SGS Pharma have ISO 27001 certification ?

According to Rankiteo,SGS Pharma is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does SGS Pharma operate in ?

SGS Pharma operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does SGS Pharma have ?

SGS Pharma employs approximately None employees people worldwide.

Does SGS Pharma own any subsidiaries ?

SGS Pharma presently has no subsidiaries across any sectors.

How many LinkedIn followers does SGS Pharma have ?

SGS Pharma's official LinkedIn profile has approximately 22,761 followers.

What is the NAICS classification code for SGS Pharma ?

SGS Pharma is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does SGS Pharma have a Crunchbase profile ?

No, SGS Pharma does not have a profile on Crunchbase.

Does SGS Pharma have a LinkedIn profile ?

Yes, SGS Pharma maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/sgs-health-science.

How many cybersecurity incidents has SGS Pharma experienced ?

As of June 30, 2026, Rankiteo reports that SGS Pharma has not experienced any cybersecurity incidents.

How many peer or competitor companies does SGS Pharma have ?

SGS Pharma has an estimated 5,696 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

SGS Pharma

Boost Score +25 with badge (5 left)

759

/1000

Fair

784

/1000

Fair

SGS Pharma Vendor Cyber Rating & Cyber Score

sgs.com

Add Your Compliance Badge

SGS Pharma supports pharmaceutical, biopharmaceutical and CDMO organisations across the full product lifecycle, from early R&D and preclinical development through clinical trials, commercial manufacturing and post-market assurance. Our services span pharma CRO clinical research and GMP / GLP drug development and testing. SGS Pharma operates through two core divisions. Clinical Research delivers early-phase CRO services including clinical pharmacology, Phase I–IIa trials, biometrics, data management, biostatistics, medical writing, pharmacovigilance and regulatory support. Drug Development provides GMP and GLP pharmaceutical and biopharmaceutical testing for small molecules, biologics, biosimilars, cell and gene therapies, ATMPs,

SGS Pharma A.I CyberSecurity Scoring

Scoring History

SGS Pharma

SGS Pharma CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

SGS Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for SGS Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for SGS Pharma in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for SGS Pharma in 2026.

Incident Types SGS Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for SGS Pharma in 2026.

Incident History - SGS Pharma (X = Date, Y = Severity)

Loading…

SUBSIDIARY

SGS Pharma Subsidiaries

SGS Pharma

Pharmaceutical Manufacturing

Website: https://www.sgs.com/en/industry/pharma

Company Size: 10,000+ employees

SGSProfessional Services

BrightsightIT System Testing and Evaluation

SGS Natural ResourcesAußenhandel und internationale Entwicklung

SGS Certification SolutionsInternational Trade and Development

SGS Supply Chain AssuranceTransportation, Logistics, Supply Chain and Storage

SGS Cosmetics & HygieneHerstellung von Körperpflegeprodukten

Loading…

SGS Pharma Similar Companies

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Loading…

NEWS

SGS Pharma CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 06, 2026 08:00 AM

SGS enhances Digital Trust capabilities by acquiring Panacea Infosec

BAAR, SWITZERLAND, January 6, 2026 /EINPresswire.com/ — SGS is reinforcing its dedication to digital trust and payment card security solutions through the...

Read Article

January 05, 2026 08:00 AM

Swiss inspection firm SGS acquires Indian cybersecurity firm

+Get the most important news from Switzerland in your inbox. This acquisition, the amount of which was not disclosed, is expected to...

Read Article

November 27, 2025 08:00 AM

SGS Highlights Cybersecurity Capabilities With World's First EU RED-NB Certification and Cybersecurity Mark

SGS awards Ruijie Networks the world's first EU RED-NB certification and Cybersecurity Mark, reinforcing its leadership in cybersecurity and...

Read Article

November 03, 2025 08:00 AM

Owlet receives global cybersecurity certification for baby monitor

Baby monitoring company Owlet announced that its Dream Sight video monitoring device has earned the SGS Cybersecurity Mark, a global...

Read Article

January 08, 2025 04:48 AM

U.S. Pharmaceutical Packaging Services Market Report, 2030

The U.S. pharmaceutical packaging services market size was estimated at USD 2.82 billion in 2024 and is expected to expand at a CAGR of 9.0% from 2025 to...

Read Article

March 09, 2021 08:00 AM

Seize digital opportunities and mitigate cyber threats with SGS Cybersecurity Services

CNW/ -- SGS, the world's leading inspection, verification, testing and certification company, helps clients seize digital opportunities...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-8023

SUMMARY

Zephyr's HTTP server (subsys/net/lib/http) provides a static-filesystem resource type (HTTP_RESOURCE_TYPE_STATIC_FS, available when CONFIG_FILE_SYSTEM is enabled) that serves files from a configured root directory. Before this fix, both the HTTP/1 and HTTP/2 front-ends placed the raw, attacker-controlled request path into client-url_buffer (assembled in on_url() for HTTP/1 and copied verbatim from the :path pseudo-header for HTTP/2) without resolving ./.. segments. The static-FS handler then built the on-disk filename by directly concatenating the configured root with that raw URL (snprintk(fname, ..., "%s%s", static_fs_detail-fs_path, client-url_buffer) at http_server_http1.c:603 and http_server_http2.c:490) and opened it with fs_open(fname, FS_O_READ). Because the handler is reached via wildcard/leading-dir (fnmatch FNM_LEADING_DIR) or fallback resource matching, a request such as GET /<prefix/../../<file is dispatched to the handler and, after the underlying filesystem (e.g. LittleFS/FAT) resolves the .. segments, escapes the configured web root, letting an unauthenticated remote client read arbitrary readable files on the mounted volume (information disclosure). The HTTP server requires no TLS or authentication to reach this path. The fix adds http_server_remove_dot_segments(), which canonicalizes the path portion of the URL before resource lookup in both protocol handlers, neutralizing the traversal. Affects releases v4.0.0 through v4.4.0 for deployments that register a static-filesystem resource.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-7656

SUMMARY

The IPv6 Neighbor Discovery handlers in subsys/net/ip/ipv6_nbr.c (handle_ra_input, handle_ns_input, handle_na_input) used an incorrect boolean expression that combined the RFC 4861 validity checks with the ICMPv6 code check using the wrong operator precedence: the form was '((length/hop/source/target checks) && (icmp_hdr-code != 0))'. Because every legitimate ND message carries ICMPv6 code 0, an attacker setting code == 0 (the normal value) caused the entire predicate to evaluate false, so the packet was never dropped and all of the other checks were silently skipped. The bypassed checks include the mandatory Hop Limit == 255 verification (which proves an ND packet originated on-link and was not forwarded) and, for Router Advertisements, the requirement that the source be a link-local address, as well as multicast-target sanity checks. As a result, an adjacent on-link attacker — and, because the Hop-Limit-255 guard is bypassed, potentially a remote/off-link attacker whose packets would otherwise be rejected — can have forged Router Advertisement, Neighbor Solicitation, and Neighbor Advertisement messages accepted. A forged RA lets the attacker reconfigure the victim's default router, on-link prefixes (SLAAC), MTU, reachable/retransmit timers, and (with CONFIG_NET_IPV6_RA_RDNSS) DNS servers, while forged NS/NA enable neighbor-cache poisoning, enabling man-in-the-middle, traffic redirection, and denial of service. The flaw is an input-validation/authentication weakness rather than a memory-safety issue: the underlying packet-parsing primitives (net_pkt_get_data, net_pkt_read, net_pkt_skip) are independently bounds-safe and the validated 'length' is the true buffer length, so skipping the length check causes no out-of-bounds access. The defect has existed since the logic was introduced in 2018 and shipped in all releases through v4.4.0; it is fixed by splitting the condition so any failing check drops the packet.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

2.8

REFERENCES

CVE-2026-51219

SUMMARY

A heap buffer overflow in the HighPriorityASDUQueue_hasUnconfirmedIMessages function of lib60870 v2.3.3 to v2.3.6 allows attackers to cause a Denial of Service (DoS) via a crafted payload.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-51218

SUMMARY

A heap buffer overflow in the TS7Worker::PerformFunctionWrite() function (/core/s7_server.cpp) of snap7 v1.4.3 allows attackers to cause a Denial of Service (DoS) via a crafted packet.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-10648

SUMMARY

mcumgr_serial_process_frag() in subsys/mgmt/mcumgr/transport/src/serial_util.c calls net_buf_reset() on the result of smp_packet_alloc() before checking it for NULL. smp_packet_alloc() uses net_buf_alloc(K_NO_WAIT) against the shared MCUmgr packet pool (CONFIG_MCUMGR_TRANSPORT_NETBUF_COUNT, default 4), which returns NULL when the pool is exhausted. In default builds the __ASSERT_NO_MSG in net_buf_reset is a no-op, so net_buf_simple_reset writes through the NULL pointer (buf->len = 0; buf->data = buf->__buf), causing a fault/crash. The fragment data reaches this code from attacker-controlled bytes on the MCUmgr serial/UART/shell-console transports (smp_uart.c, smp_raw_uart.c, smp_shell.c), and a fresh buffer is allocated at the start of essentially every new packet. An attacker on the serial/console link can flood the transport to drive the 4-entry buffer pool to exhaustion and induce the NULL dereference, crashing the device (denial of service). The defect was introduced after the original MCUmgr rework and shipped in Zephyr v4.4.0. The fix moves the NULL check ahead of net_buf_reset.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 6.2)

cvss3

Base Score: 6.2

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.5

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…